Another study ‘changes practice’ in high-risk bladder cancer

(MedPage Today) – Berlin – The addition of durvalumab (Imfinzi) to induction and maintenance therapy for bacille Calmette-Guérin (BCG) significantly improved disease-free survival (DFS) in patients with high-risk, non-muscle-invasive naive bladder.